AKBA Stock — Akebia Ther

Akebia Ther (AKBA)

Updated October 16, 2026.

AKBA is a Stock. Total return is -97.5% over the past 12.6 years, 500.5 points behind SPY at 403.0%.

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease patients, with marketed products including Vafseo (an oral treatment for anemia in chronic kidney disease) and Auryxia (for controlling phosphorus levels and treating iron deficiency anemia), along with earlier-stage candidates in development for acute kidney injury and other conditions. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to specialized healthcare companies with commercial-stage therapies and clinical development pipelines, though it carries the typical risks associated with biopharmaceutical operations.

AKBA performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.5% over the past 12.6 years, 500.5 points behind SPY at 403.0%. Over the past year its total return — price change plus distributions reinvested — is -77.0%. Its deepest 1-year drawdown was 78.9%.

AKBA key facts

Asset type

Stock

Asset class

Equity

Inception date

03/20/2014

Distribution frequency

None

Last close

$0.67 (as of 2026-10-16)

Market cap

$185,661,184

Average volume

7054348.0

Beta

0.18

Payout ratio

0.0%

Forward P/E

28.7356

EPS

$-0.13

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AKBA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 78.9%.

Who may consider AKBA — and who may not

It is a weaker fit for investors who need monthly cash flow (AKBA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AKBA

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions